Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest

Several population groups display an increased risk of severe disease and mortality following SARS-CoV-2 infection. These include those who are immunocompromised (IC), have a cancer diagnosis, human immunodeficiency virus (HIV) infection or chronic inflammatory disease including autoimmune disease,...

Descripción completa

Detalles Bibliográficos
Autores principales: Moss, Paul, Berenbaum, Francis, Curigliano, Giuseppe, Grupper, Ayelet, Berg, Thomas, Pather, Shanti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135663/
https://www.ncbi.nlm.nih.gov/pubmed/35718592
http://dx.doi.org/10.1016/j.vaccine.2022.05.067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135663/
https://www.ncbi.nlm.nih.gov/pubmed/35718592
http://dx.doi.org/10.1016/j.vaccine.2022.05.067

Ejemplares similares